@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma
@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce
@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce
> Belgium's UCB sued Sun Pharmaceutical Industries over the latter's planned generic version of the seizure drug Vimpat. Report (reg. req.)
> Indian drugmakers are struggling to make a dent in Japan's generics market, the world's second largest, with only a few so far able to establish a presence there. Report
> The FDA expanded the age range for Novartis' ($NVS) meningococcal vaccine Menveo, allowing the drugmaker to offer one vaccine to infants, children and adolescents. Report
> Sanofi's ($SNY) Indian unit inked a deal with the country's largest wind-turbine maker for a 2.1 megawatt off-site windmill installation. Report
> The FDA gave its blessing to Bayer's animal health drugs ProstaMate and OvaCyst, used to manage reproduction. Report
> The FDA warned that acetaminophen can cause rare but serious skin diseases. Report
> Despite new price cuts in effect in India, some pharmacies are selling multinational drugmakers' products at the old prices. Report
> India's Piramal plans to raise about $61.57 million by issuing 11.75% commercial paper. Report
Medical Device News
@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev
@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce
@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce
@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from FierceDrugDelivery | Follow @MichaelGFierce
> M&A report: Theragenics agrees to $68M buyout. Story
> Stryker CEO: So far, so good after one year. Item
Biotech News
@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech
@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce
@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce
> BioMotiv garners $46M for early-stage licensing deals, R&D work. Article
> The FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report
> Bayer aims at hot cancer immunotherapy race with $540M R&D deal. News
CRO News
> Charles River boosts sales as charges drag profits. Article
> INC expands in Japan as local market soars. Story
> Clinipace reaches into the north with CRO partnership. Item
> Quintiles posts flat revenue as charges swallow profits. Report
> Covance swings to profit despite tough early-phase market. More
> KKR buying RPS, planning to merge it with PRA. Article
Biotech IT News
> China pharma R&D drives expanded use of Medidata software. News
> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More
> Accelrys to ax 80 jobs after drop in quarterly profits. News
> Battle against breast cancer goes open source. Story
> Ex-Yahoo CEO backs genomics big data startup Bina. Article
And Finally... Antibiotic resistance in hospital-acquired illness is much greater than the Centers for Disease Control and Prevention (CDC) previously thought. Report